Standout Papers

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (... 2019 2026 2021 2023 3.7k
  1. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges (2020)
    Chih‐Cheng Lai, Wen‐Chien Ko et al. International Journal of Antimicrobial Agents
  2. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths (2020)
    Chih-Cheng Lai, Cheng‐Yi Wang et al. Journal of Microbiology Immunology and Infection
  3. Are children less susceptible to COVID-19? (2020)
    Ping‐Ing Lee, Po-Yen Chen et al. Journal of Microbiology Immunology and Infection
  4. Nanoparticles in the Treatment of Infections Caused by Multidrug-Resistant Organisms (2019)
    Nan–Yao Lee, Wen‐Chien Ko et al. Frontiers in Pharmacology
  5. The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program (2019)
    Daniel J. Diekema, Po‐Ren Hsueh et al. Antimicrobial Agents and Chemotherapy
  6. Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options (2019)
    Chau‐Chyun Sheu, Ya-Ting Chang et al. Frontiers in Microbiology
  7. Mycobacterium abscessusComplex Infections in Humans (2015)
    Meng‐Rui Lee, Wang‐Huei Sheng et al. Emerging infectious diseases
  8. Increased antimicrobial resistance during the COVID-19 pandemic (2021)
    Chih‐Cheng Lai, Shey‐Ying Chen et al. International Journal of Antimicrobial Agents
  9. Global Threat of Carbapenem-Resistant Gram-Negative Bacteria (2022)
    Shio-Shin Jean, Dorji Harnod et al. Frontiers in Cellular and Infection Microbiology

Immediate Impact

4 by Nobel laureates 9 from Science/Nature 83 standout
Sub-graph 1 of 21

Citing Papers

Multidrug-resistant Gram-negative bacterial infections
2025 Standout
Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance
2024 Standout
42 intermediate papers

Works of Po‐Ren Hsueh being referenced

In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020
2023
Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020
2022
and 49 more

Author Peers

Author Last Decade Papers Cites
Po‐Ren Hsueh 12286 14841 8482 960 36.9k
Matthew E. Falagas 15007 7924 16665 589 46.4k
Barry N. Kreiswirth 12557 24426 9734 505 37.5k
John G. Bartlett 19372 15127 3968 391 42.4k
Wen‐Chien Ko 6057 7436 6369 656 24.7k
Barbara E. Murray 7472 19136 6762 330 34.5k
Rafael Cantón 8163 6804 15177 749 29.3k
Robert A. Weinstein 7122 9149 6142 344 26.8k
Marc J. M. Bonten 8388 8462 4638 546 23.9k
Yehuda Carmeli 8487 8084 19334 328 32.9k
Fernando Baquero 5473 5722 12237 482 28.6k

All Works

Loading papers...

Rankless by CCL
2026